Literature DB >> 11272873

Has there been a turning point in the numbers of AIDS and HIV antibody positive cases in Ireland?

G E Kelly1, S M Clarke.   

Abstract

BACKGROUND: Major developments in the prevention and treatment of human immunodeficiency virus (HIV) infection and acquired immunodeficiency syndrome (AIDS) have taken place in recent years. Changes in the size of the HIV and AIDS epidemic need to be monitored to assess these developments and plan future services. AIMS: To describe temporal trends in the incidence of HIV and AIDS in Ireland, describing separately the major risk groups, and to explore possible associations between these trends with developments in care.
METHODS: The annual numbers of HIV and AIDS in Ireland were analysed to determine whether there has been a turning point in incidence.
RESULTS: For AIDS, there has been an overall decrease in numbers since 1993, with both homosexual and intravenous drug users (IDU) risk groups exhibiting a decrease. For HIV antibody positive individuals, overall numbers have remained constant. However, there has been an upward trend in the heterosexual risk group and a downward trend in the IDU risk group. Thus both AIDS and HIV numbers exhibit turning points.
CONCLUSIONS: Declines in HIV and AIDS incidence in the homosexual and IDU risk groups are indirectly attributable to health safety and treatment programmes. The increase in HIV antibody positive cases among heterosexuals may reflect a relapse in safe sex behaviour.

Entities:  

Mesh:

Year:  2000        PMID: 11272873     DOI: 10.1007/bf03167692

Source DB:  PubMed          Journal:  Ir J Med Sci        ISSN: 0021-1265            Impact factor:   1.568


  14 in total

1.  HIV incidence among injection drug users in New York City, 1992-1997: evidence for a declining epidemic.

Authors:  D C Des Jarlais; M Marmor; P Friedmann; S Titus; E Aviles; S Deren; L Torian; D Glebatis; C Murrill; E Monterroso; S R Friedman
Journal:  Am J Public Health       Date:  2000-03       Impact factor: 9.308

2.  New cases seen at genitourinary medicine clinics: England 1997.

Authors:  G Hughes; I Simms; P A Rogers; A V Swan; M Catchpole
Journal:  Commun Dis Rep CDR Suppl       Date:  1998-12

Review 3.  HIV-protease inhibitors.

Authors:  C Flexner
Journal:  N Engl J Med       Date:  1998-04-30       Impact factor: 91.245

4.  A method to test for a recent increase in HIV-1 seroconversion incidence: results from the Multicenter AIDS Cohort Study (MACS).

Authors:  S Y Zhou; L A Kingsley; J M Taylor; J S Chmiel; D Y He; D R Hoover
Journal:  Stat Med       Date:  1993-01-30       Impact factor: 2.373

5.  Prevalence of HIV and associated risk behaviour in attendees at a Dublin needle exchange.

Authors:  Z Johnson; M O'Connor; L Pomeroy; H Johnson; J Barry; M Scully; E Fitzpatrick
Journal:  Addiction       Date:  1994-05       Impact factor: 6.526

6.  Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators.

Authors:  F J Palella; K M Delaney; A C Moorman; M O Loveless; J Fuhrer; G A Satten; D J Aschman; S D Holmberg
Journal:  N Engl J Med       Date:  1998-03-26       Impact factor: 91.245

7.  HIV incidence among injecting drug users in New York City syringe-exchange programmes.

Authors:  D C Des Jarlais; M Marmor; D Paone; S Titus; Q Shi; T Perlis; B Jose; S R Friedman
Journal:  Lancet       Date:  1996-10-12       Impact factor: 79.321

8.  The incidence and prevalence of AIDS and prevalence of other severe HIV disease in England and Wales for 1995 to 1999: projections using data to the end of 1994.

Authors: 
Journal:  Commun Dis Rep CDR Rev       Date:  1996-01-05

9.  The use of primary care services by drug users attending a HIV prevention unit.

Authors:  G Bury; F O'Kelly; L Pomeroy
Journal:  Ir Med J       Date:  1993-03

Review 10.  Antiretroviral therapy for HIV infection in 1998: updated recommendations of the International AIDS Society-USA Panel.

Authors:  C C Carpenter; M A Fischl; S M Hammer; M S Hirsch; D M Jacobsen; D A Katzenstein; J S Montaner; D D Richman; M S Saag; R T Schooley; M A Thompson; S Vella; P G Yeni; P A Volberding
Journal:  JAMA       Date:  1998-07-01       Impact factor: 56.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.